AttadnEnt II - Ifege 9 
9309-057 
9309-058 
9312 - 059 * 
9312-060 
9312-061 
9312 - 062 * 
9312-063 
9312-064 
(T/HIV) 
Wong-Staal, Flossie; Poeschla, Eric; and Looney, David; University of California, San Diego, 
California; A Phase I Clinical Trial to Evaluate the Safety and Effects in HIV-1 Infected Humans of 
Autologous Lymphocytes Transduced with a Ribozyme that Cleaves HIV-1 RNA. 
RAC Approval: 9-10-93/NTH Approval: 10-25-94 
(T/V/ C/Melanoma) 
Economou, James S. and Glasby, John A.; University of California Medical Center, Los Angeles, 
California; Genetically Engineered Autologous Tumor Vaccines Producing Interleukin-2 for the 
Treatment of Metastatic Melanoma. 
RAC Approval: 9-10-93/NIH Approval: 12-2-93 
(T/C/Leptomenlngeal Carcinomatosis) 
Oldfield, Edward H. and Ram, Zvi; NIH, Bethesda, Maryland; Intrathecal Gene Therapy for the 
Treatment of Leptomeningeal Carcinomatosis. 
RAC Approval: 12-2-93/N1H Approval: 1-20-94 
Minor Modification: 7-5-94 
(T/V/C) 
Sobol. Robert E. and Rovston. Ivor: San Diego Regional Cancer Center. San Dieeo. California: 
Injection of Colon Carcinoma Patients with Autologous Irradiated Tumor Cells and Fibroblasts 
Genetically Modified to Secrete Interleukin-2. 
RAC Approval: 12-2-93/NTH Approval: Fending 
(T/IGD/Gaucher Disease) 
Schuening, Friedrich; Fred Hutchinson Cancer Research Center, Seattle, Washington; Retrovirus- 
Mediated Transfer of the cDNA for Human Glucocerebrosidase into Peripheral Blood Repopulating 
Cells of Patients with Gaucher’s Disease. 
RAC Approval: 12-2-93/NIH Approval: 11-15-94 
(T/HIV) 
Haubrich, Richard; University of California at San Diego Treatment Center, San Diego, California, 
and Merritt, James A.; Viagene, Inc., San Diego, California; An Open Label, Phase I/II Clinical 
Trial to Evaluate the Safety and Biological Activity of HIV-IT(V) (HIV-1 IIBenv /Retroviral Vector) in 
HIV-1 Infected Subjects. 
RAC Approval: 12-3-93 /NIH Approval: 4-19-94 
Minor Modification: 7-11-94 
Minor Modification: 10-12-94 
CLOSED: 10-13-94 
(T/V/ C/Melanoma) 
Sznol, Mario; National Institutes of Health, Frederick, Maryland; A Phase I Trial of B7-Transfected 
Lethally Irradiated Allogeneic Melanoma Cell Lines to Induce Cell Mediated Immunity Against Tumor- 
Associated Antigens Presented by HLA-A2 or HLA-A1 in Patients with Stage TV Melanoma. 
RAC Approval: 12-3-93/NIH Approval: 4-19-94 
(T/C/Colorectal) 
Rubin, Joseph; Mayo Clinic, Rochester, Minnesota; Phase I Study of Immunotherapy of Advanced 
Colorectal Carcinoma by Direct Gene Transfer into Hepatic Metastases. 
RAC Approval: 12-3-93/NIH Approval: 4-19-94 
Recombinant DNA Research, Volume 20 
[497] 
